Vaccination with SIV mac239 Dnef provides robust protection against subsequent challenge with wild-type simian immunodeficiency virus (SIV), but safety issues have precluded designing an HIV-1 vaccine based on a live-attenuated virus concept. Safe immunogens and adjuvants that could reproduce identified immune correlates of SIV mac239 Dnef protection therefore offer an alternative path for development of an HIV vaccine. Here we describe SIV envelope trimeric gp41 (gp41t) immunogens based on a protective correlate of antibodies to gp41t concentrated on the path of virus entry by the neonatal Fc receptor (FcRn) in cervical vaginal epithelium. We developed a gp41t immunogen-monophosphoryl lipid A adjuvant liposomal nanoparticle for intramuscular (i.m.) immunization and a gp41t-Fc immunogen for intranasal immunization for pilot studies in mice, rabbits, and rhesus macaques. Repeated immunizations to mimic persistent antigen exposure in infection elicited gp41t antibodies in rhesus macaques that were detectable in FcRnþ cervical vaginal epithelium, thus recapitulating one key feature of SIV mac239 Dnef vaccinated and protected animals. Although this strategy did not reproduce the system of local production of antibody in SIV mac239 Dnef-vaccinated animals, passive immunization experiments supported the concept that sufficiently high levels of antibody can be concentrated by the FcRn at mucosal frontlines, thus setting the stage for assessing protection against vaginal challenge by gp41t immunization.
Introduction
In the quest for an effective HIV-1 vaccine, particularly to prevent transmission to the young women who bear the brunt of infection in the pandemic's epicenter in Africa [1, 2] , we have been seeking design principles to guide vaccine development by identifying correlates of the robust protection afforded by the live-attenuated SIV mac239 Dnef vaccine in the rhesus macaque model of HIV transmission to women [3] [4] [5] [6] [7] [8] . With those principles in hand, we could then design alternatives to circumvent the safety issues associated with SIV mac239 Dnef vaccination [9, 10] .
We recently found that persistent SIV mac239 Dnef infection induced collections of plasma cells producing antibodies (Abs) to trimeric gp41 (gp41t) positioned beneath FcRnexpressing cervical and vaginal epithelium. This organized mucosal epithelial immune system concentrates Abs on the path of virus entry on subsequent vaginal challenge with wild-type simian immunodeficiency virus (SIV), and thus could thereby account for the observed constraints on establishment of founder populations of infected cells at the portal of entry [8] . Here we describe the design of immunogens and vaccine strategies that mimic this protective correlate of gp41t-Abs concentrated at mucosal frontlines without the immune response to local viral replication, thus potentially providing a safer approach to live-attenuated vaccination.
Materials and methods
Trimeric gp41 liposomal nanoparticle immunogen The anti-gp41t Abs induced by SIV mac239 Dnef vaccination are likely elicited by conformational, immunodominant cluster I and II epitopes presented on gp41 trimer stumps [11] [12] [13] . We generated an immunogen that mimicked these epitopes that could be displayed at high density on liposomes into which the lipophilic toll-like receptor (TLR)-based adjuvant, monophosphoryl lipid A (MPLA), could be incorporated [14, 15] . The recombinant gp41 ectodomain shown schematically in Fig. 1 was expressed in 293F cells from a plasmid with human cytomegalovirus immediate early promoter (Genlantis, San Diego, California, USA) that included gp160 residues 554-676 (SIVmac239 numbering), flanked N-terminally by an IgK signal sequence to target the protein to the endoplasmic reticulum (ER) for glycosylation, disulfide bond formation, and secretion; and C-terminally, by a strep tag for affinity purification from Freestyle 293 media (Gibco Thermo Fisher, Waltham, Massachusetts, USA) using StrepTactin resin (IBA, Goettingen, Germany). Avidin was added to the filtered, concentrated media to block biotin before loading onto the column. The column was washed with phosphate-buffered saline (PBS), and protein eluted with 2.5 mmol/l desthiobiotin in PBS. The eluent was concentrated and loaded on a Superdex200 column (GE Healthcare) to purify a 66-kDa protein from higher molecular weight aggregates (approx. 1 mg from 2 l). The predicted 16 kDa recombinant purified protein migrated at 22 kDa by SDS-PAGE under reducing conditions ( Fig. 1c) , which is consistent with three predicted sites of glycosylation (2 kDa per glycan), and eluted at 66 kDa by size exclusion chromatography (Fig. 1c ). This size is consistent with a trimeric quaternary structure, likely the six-helix bundle as previously solved by X-ray crystallography and NMR [16] shown in Fig. 1b .
Stealth liposomes displaying gp41t were prepared as described previously [17] by first linking the gp41t trimer to pegylated DSPE using maleimide chemistry (Fig. 2a ). The trimeric protein was reacted with 2.5 molar equivalents of N-succinimidy 3-(pyridyldithio)-propionate (Pierce) and the disulfide bonds in the gp41t trimeric structure were preserved by deprotecting the 2-pyridyldithio group with dithiothreitol at pH 5.5 in sodium acetate. On average, 1.25 molar equivalents of thiol were introduced per trimer; therefore, on average each trimer had only one attached lipid. Following coupling of the thiol-modified gp41t with Mal-PEG 2000 -DSPE (NOF America) and column chromatography to remove any unreacted protein, lipid-modified gp41t was used to hydrate dried lipids to produce a final mol ratio of 60 : 35:4.9 : 0.1 of distearoyl phosphatidylcholine (DSPC) (Avanti Polar Lipids, Alabaster, Alabama, USA), cholesterol (Sigma-Aldrich, St Louis, Missouri, USA), PEG 2000 -DSPE, and gp41t-PEG-DSPE ( Fig. 2b ). When MPLA was included, 5 mol% DSPC was replaced by 5 mol% MPLA (Avanti Polar Lipids). Lipids were hydrated in PBS containing the gp41t-PEG-DSPE to achieve a total lipid concentration of 5 mmol/l. Following rigorous sonication, liposomes were extruded using a hand extruder (Avanti Polar Lipids) through an 800, 200, and finally 100 nm filters.
Trimeric gp41-Fc fusion protein
Three copies of the sgp41t described above were linked in tandem and fused at the C-terminus to the Fc domain of the rhesus macaque IgG1 K322A mutant, flanked Nterminally by an IgK signal sequence to target the protein to the ER for glycosylation, disulfide bond formation, and secretion; and C-terminally, by a strep tag. The protein was purified in the same way as gp41t using StrepTactin affinity and size exclusion chromatography ( Fig. 1b and c) [18] .
Animals and vaccination
In the initial assessment of the liposomal gp41t-MPLA immunogen/adjuvant, four 8-week-old female BALB/C mice were primed and boosted at 3 weeks with 10 mg of gp41t incorporated into liposomes with or without 22.5 mg MPLA in 200 ml PBS by intravenous administration via the tail vein. Ocular bleeds were taken before For the pilot experiment to evaluate the immunogens and adjuvants in the rhesus macaque animal model of HIV-1 transmission to women, four adult female rhesus monkeys of Indian origin (Macaca mulatta) were obtained from the Yerkes National Primate Center colony and housed in pairs. Monkeys were immunized under anesthesia following two distinct protocols: two monkeys (RTe8 and ROz6) received 100 mg soluble gp41 trimers presented by liposomes (sgp41t-stealth liposomes) containing MPLA, along with 500 mg CpG oliogodeoxynucleotides (ODNs) (TCGTCGTTTTGTCGTT TTGCTGTT; Trilink Biotechnologies, San Diego, California, USA) in 1 ml and 1 ml Emulsigen-D (MVP Laboratories; Omaha, Nebraska, USA) divided equally between the right and left leg quadriceps (i.m.) on day 0, and months 1, 3, and 6 (Rte8), at which point RTe8 had to be euthanized because of chronic diarrhea and associated weight loss that exceeded IACUC-approved limits. Necropsy findings were normal and the diarrhea was attributed to stress and not to immunization. ROz6 received additional immunizations at months 9 and 12. As described under results, we also generated a gp41tmacaque IgG1 Fc fusion protein as an immunogen for intranasal (i.n.) administration to target the female reproductive tract (FRT) as described for herpes simplex virus-2 (HSV-2) studies [18] . The other two monkeys, RBq-6 and RDj-11, initially received 100 mg sgp41t-Fc with 3 mg MPLA and 500 mg CpG ODNs in 400 ml, dispensed drop-wise into both nares on day 0 and months 1, 3, 6, 9, and 12. Because of low titers in response to i.n. immunization alone, these two monkeys additionally received the same i.m. immunizations as ROz-6 and RTe-8 on months 3, 6, 9, and 13. Serum and plasma cells were collected over the course of the experiment and cervical vaginal swabs were also taken. Plasma was heat inactivated for 1 h at 568C and filtered for ELISA and SIV western blot analysis. The animals were cared for in conformance to the guidelines of the Committee on the Care and Use of Laboratory Animals [(U.S.), 1996]. All experimental protocols and procedures were reviewed and approved by the Emory Institutional Animal Care and Use Committee.
Monoclonal antibody 4.9C production and passive immunization Rhesus MAb 4.9C was originally produced by a Rhesus B cell line derived from jejunal lamina propria lymphocytes of a monkey infected by low-dose, intracolonic administration of SIV 17E-Fr [19] , as previously described [20] . MAb 4.9C was found to react identically with oligomeric gp41 in western blots to antibodies to gp41 elicited by SIV mac239 Dnef vaccination [8] . formulated in sodium citrate buffer, pH 6. Endotoxin level was less than 0.1 EU/mg. MAb 4.9C at 25 or 50 mg/kg was administered i.v. and sera and cervical vaginal lavage (CVL) fluids were collected 1, 6, and 24 h post injection. Mab 4.9C concentrations were assessed by ELISA and SIV western blot by the same methods described for the active immunization experiment.
Tissue collection and processing Animals were euthanized 14 days after the last boost. At the time of euthanasia, tissues were collected and fixed in 4% paraformaldehyde or SafeFix II (Fisher Scientific, Fair Lawn, New Jersey, USA) and embedded in paraffin for later sectioning and analysis, as previously described [8] .
ELISA assays
Total IgG (IgGT) and sgp41t-specific IgG titers were assessed in serum and CVL fluid (CVF) by ELISA. 50 ml/well of 1 mg/ml unconjugated antimouse/rabbit/ human IgG F(ab 0 )2 (Jackson ImmunoResearch, West Grove, Pennsylvania, USA) or sgp41t in PBS was added to 96-well high bind microtiter plates (Corning) and incubated overnight at 48C (antihuman antibodies crossreact well with those of rhesus macaque). Plates were washed (3Â 100 ml PBS-0.01% tween20) and blocked for 1 h at room temperature in 100 ml/well of 3% bovine serum albumin (BSA) in PBS. Plates were washed and 50 ml/well of sample dilutions added. In general, starting dilutions for serum were around 50Â or 5000Â for sgp41t specific or IgG total ELISAs, respectively. For CVL, starting dilutions were 5Â and 50Â for sgp41t-specific and IgGT-ELISAs, respectively, with some further optimization required. Samples were diluted with PBS-0.01% tween20 þ 1%BSA. Titration curves were created by diluting duplicate samples 6Â down each column of the 96-well plate. Plates were incubated 2 h at room temperature, and then washed. For urea washes to remove low-affinity antibodies, 50 ml/well of 6 mol/l urea in water was added for 10 min before washing the plates. horse radish peroxidase-conjugated antimouse/ rabbit/or human IgG fc fragment-specific antibody (Jackson ImmunoResearch) was diluted 1 : 15 000 in PBS-0.01% tween20 þ 1%BSA and 50 ml/well was added to plates. Plates were incubated for 1 h at room temperature, washed and developed in 50 ml/well of tetramethylbenzidine substrate (Thermo Scientific Pierce). The reaction was stopped with 50 ml/well of 1 mol/l sulfuric acid, and the absorbance at 450 nm was recorded for each well. Standard IgG curves were made for macaque samples using protein A/G purified IgG from rhesus macaque serum. The values of concentration that gives half-maximal binding (EC 50 ) were calculated from nonlinear regression analysis of the absorbance values using Prism. Antigen-capture ELISAs were attempted to exclude the possibility that the above direct capture format obscures a detectable ELISA correlate between early (unprotected) and later (protected) time points as is observed by western blot, as described under results. First, 50 ml of 2 mg/ml antistrep tag monoclonal antibody (2-1507-001 IBA) in PBS was added to wells and incubated O/N at 48C. Liquid was removed and wells were blocked with 100 ml 3%BSA or 5% milk for 1 h. Wells were washed 3Â with PBS-T before adding 50 ml of the strep-tagged sgp41t at 2 mg/ml in PBS-T and incubated for 2 h at room temperature. Wells were washed with PBS-T 3Â before proceeding with the serum dilution incubations as described above. This ELISA gave a poor signal to background ratio and so a similar ELISA was attempted using an anti-HIS tag mAb (MA1-21315; Thermo Fisher) and a HIS-tagged version of the sgp41t protein where 8Â HIS replaced the strep tag. As observed with direct coating, antigen-capture offered no observable titer correlate between protected and unprotected serums. Purification of the His-tagged sgp41 was similar to the streptactin purification protocol except nickel triolotriacetic acid (Ni-NTA) was used as purification resin. Imidazole (10 mmol/l, pH 7.5) was added to supernatant and loaded on column. The column was washed with PBS þ 20 mmol/l imidazole and protein was eluted with 300 mmol/l imidazole pH 7.5 100 mmol/l NaCl.
Neutralization assays
Neutralization assays were performed as previously described [8, 22, 23] . In brief, protease inhibitors and the nondenaturing detergents in the tissue extracts were removed by ultrafiltration and replaced by RPMI 1640 containing 10% normal rhesus sera. Tissue extracts and sera were serially diluted (10-fold) in RPMI 1640 containing 10% normal rhesus sera, incubated with TCLA-SIV mac251 , SIV mac251 32H , or SIV mac251 vaginal challenge stock before the addition of C8166-45-SEAP reporter cells (multiplicity of infection ¼ 0.05) and subsequent measurement of Secreted Alkaline Phosphatase (SEAP) activities.
Isolation of antibodies from tissues and cervical vaginal fluids and western blot analysis
Isolation of antibodies from tissues and cervical vaginal fluid, and western blot analyses followed previously published protocols [8, 24] .
Reverse immunohistochemistry
Reverse immunohistochemistry (RIHC) staining to detect gp41-specific antibody in cells was performed as previously described [8] .
Results

Gp41t-immunogen design
We previously showed that Abs to gp41t concentrated by the FcRn in cervical reserve and vaginal epithelium was one correlate of protection conferred by SIV mac239 Dnef vaccination [8] . We sought to reproduce this correlate with immunogens and adjuvants rather than live-attenuated SIV infection, and chose a recombinant soluble gp41trimer (sgp41t) as the immunogen for several reasons. First, sgp41t had been previously shown to specifically bind to antibodies directed against gp41t that were produced in response to the SIV mac239 Dnef vaccine [8] and thus might be expected to induce antibodies similar to those elicited by vaccination. Second, gp160 residues 554-676 (SIV mac239 numbering; Fig. 1a and b) represent broadly conserved epitopes in SIV, and in HIV clades as well, and therefore the potential for heterologous binding of vaccine-induced antibodies across virus clades. Third, expressing the gp41 ectodomain as a secreted protein product, lacking the fusion peptide and truncated just before the MPER with nine N-linked glycosylated sites per trimer (Fig. 1b) , should enhance solubility, and the exclusion of the MPER should, in principle, enable us to test the role of nonneutralizing antibodies in protection. Fourth, the predicted structure of our sgp41t, shown in Fig. 1b , is a sixhelix bundle that should present trimeric conformationally relevant clusters I and II epitopes that are critical for mimicking the immunodominant epitopes on viral gp41 stumps. In particular, because cluster I loops are juxtaposed so closely in the trimer, the quaternary structure of the protein favors interactions with residues on more than one cluster I peptide to elicit conformational antibodies with reactivity with oligomeric gp41 observed in western blots [8, 25, 26] . For i.n. immunization, we also generated a gp41t macaque IgG1 Fc-fusion protein for transport to antigen presenting cells (APCs) (Fig. 1b) with a K322A mutation to disrupt C1q binding and inflammatory responses, based on the rationale described for HSV-2 to elicit protective antibody responses in the murine FRT [18] .
The sgp41t reagent was expressed and purified as described in the methods section and displayed on the surface of 80-100 nm liposomes for optimal antigen presentation and immune activation [14, 15] . MPLA was incorporated into the liposomes to further enhance immune cell activation. Liposomes displaying sgp41t as unilaminar liposomal nanoparticles (Fig. 2b) were prepared to generate an immunogen with 5-10 nm between antigens, optimal spacing for crosslinking of the B-cell receptor to induce robust B-cell activation [27] . We estimated that 0.1 mol% sgp41t would incorporate about 80 molecules of sgp41t per liposome into liposomes to approximate this optimal spacing. Following extrusion, the average diameter of liposomes displaying sgp41t was measured at 90 AE 28 nm, moderately larger than control sham liposomes that did not contain sgp41t (Fig. 2c) . MPLA was stably incorporated into the lipid bilayer to serve as a well tolerated TLR4-based adjuvant [28] .
Antibodies elicited by sgp41t-monophosphoryl lipid A-liposomes in mice and rabbits
The gp41t-liposomes alone were potent immunogens in mice and rabbits, and inclusion of MPLA further increased binding Ab titers in mice by about 10-fold (Fig. 3a) . The elicited Abs also stained the prominent gp160 oligomeric gp41t band in western blots in a similar Reproducing vaccine protection correlate Voss et al. 2433 pattern to that previously observed [8] in SIV mac239 Dnef vaccinated animals (Fig. 3b ).
Gp41t Abs concentrated in the rhesus macaque female reproductive tract
With these encouraging results in hand, we undertook a pilot experiment in rhesus macaques to determine whether we could reproduce concentration of antigp41t antibodies at the mucosal interface. We focused the strategy and assessment of the immunogens and adjuvants on showing that antigp41t antibodies could be induced and sustained at sufficiently high levels to be concentrated in the FRT in a way that mimicked SIV mac239 Dnef vaccination. The principal components of our strategy (Fig. 4a ) were prime and repeatedly boost animals over an extended period to mimic the persistent antigenic stimulus in animals infected with SIV mac239 Dnef; combine conventional i.m. inoculations with i.n. immunization with the gp41t-Fc construct that could potentially induce antibodies localized to the FRT; use a TLR9 agonist and CpG adjuvant, with the rationale that TLR9 agonists have been shown to induce strong B-cell responses in other settings [29] and have been used safely in rhesus macaques [30] .
The combination of gp41t liposomes with MPLA and CpG adjuvants stimulated production of Abs in high titers in serum in rhesus macaques that recognized gp41t (Fig. 4b) . The i.n. immunization with gp41t-Fc initially failed to induce detectable Abs reactive to gp41t, but later boosts, which included i.m. administered gp41 liposomes along with i.n. gp41-Fc, induced high titers in serum. Titers plateaued after the second boost with the i.m. immunization route (Fig. 4b) , and, in one animal euthanized after the third boost for stress-related chronic diarrhea and associated weight loss, high titers of binding Abs achieved after the third boost were equivalent to titers in the remaining three animals after two more boosts. None of the sera neutralized either TCLA or challenge virus above background inhibition observed in baseline sera (Supplemental Fig. 1 , http://links.lww.com/QAD/ A951).
The serum titers assessed 14 days post-boost five were comparable with SIV mac239 Dnef-vaccinated animals at 20 weeks after vaccination. At this time point, animals are significantly protected against challenge in contrast to 5 weeks when they are not protected, reflecting the maturation of protection [8, 31] . However, we found that the gp41t ELISA assays of sera did not reproduce this maturation of protection, as the SIV mac239 Dnef-immunized 20-week and 5-week sera were indistinguishable (Fig. 4b) . By contrast, Abs reacting with previously identified [8] oligomeric forms of gp41 (running at 160 and 80 kDa on western blotting strips) were detectable after the third boost and continued to increase with boosts four and five, and paralleled the increases at 20 weeks compared to 5 weeks in SIV mac239 Dnef-vaccinated animals (Fig. 4b) . We investigated a variety of conditions for the ELISA assay (see Methods and Supplemental Figure 2 , http://links.lww.com/QAD/A951) that did not affect the discrepancy between the assays and the important conclusion from this analysis that it is important to assess the potential efficacy of vaccination from the western blots and not ELISA titers.
Even more encouraging, Abs to oligomeric gp41t were detectable in western blots of proteins extracted from cervical vaginal tissues collected at necropsy (Fig. 4b, far  right panel) , and by RIHC, the three animals that received a prime and five boosts had comparable staining of FcRnþ-cervical reserve epithelium to animals vaccinated with SIV mac239 Dnef at the 20-week time point (Fig. 4b, representative image compared with SIVnegative control).
We also examined CVL and colorectal lavage collected with wicks, but the assays were confounded by significant difficulties in the variability of collection and contamination with blood in menses. Although gp41 was consistently detected in gp41 vaccinated CVL and colorectal washes by ELISA, the actual titers were widely variable as were total IgG levels (not shown).
Differences between immunization and SIV mac239 Dnef vaccination
The concentration of gp41t antibodies particularly in the vagina in SIV mac239 Dnef vaccinated animals has been shown to be associated with a system of local production by plasma cells and ectopic follicles, presumably reflecting persistent systemic infection and low levels of antigen at mucosal sites [8] . Although we tried to mimic persistent antigen exposure with repeated boosts with gp41tliposomes, we did not directly expose FRT tissues to antigen. It is thus perhaps not surprising that in the immunized animals we did not see induction of ectopic follicles or vaginal epithelial CXCL10 expression to recruit CXCR3þ plasma cells to the vaginal mucosa (not shown) as we had previously documented in SIV mac239 Dnef vaccinated animals despite immunization of the nasal mucosa with our gp41-Fc construct.
Passive immunization pilot and systemic delivery hypothesis
Although immunization did not reproduce the system of local antibody production in SIV mac239 Dnef vaccinated animals, it nonetheless did achieve high levels of antibodies in the FRT tissues and concentrated in FcRnþ cervical vaginal epithelium by RIHC (Fig. 4c ). This result is consistent with the idea that sustained high levels of antibody in the circulation can be concentrated in the epithelium by the FcRn. There were only sufficient resources in this pilot study to conduct a preliminary test of this hypothesis by passively immunizing with either a dose of 25 mg/kg of a rhesus monoclonal antibody (4.9C), which in western blots reacts identically with IN IN   IN+IM   IN+IM  IN+IM   IN+IM  IN+IM   IN+IM  IN+IM   IN+IM   IM IM   IM IM  IM  IM   IM  IM  IM  IM   RDj11 2  ROz6 3   RTe8 4  Month: 0 There are also antibodies against gp41 monomer and truncated forms of gp41 in the animals vaccinated with the immunogens and adjuvants that are barely detectable in the SIV mac239 Dnef vaccinated animals, which have antibodies reactive with viral capsid antigens p27 and p17. The black boxes and double headed arrow show the lack of correlation between ELISA titer and staining intensity of oligomeric gp41t bands. The red box shows the lack of correlation between ELISA titers and western blots. Only the western blots correlate with increased protection at 20 weeks. (c) RIHC. SIV-negative animal versus brown-stained gp41t-Abþ cervical reserve epithelium (arrows). Representative staining for the three animals examined after the fifth boost. Fig. 5 . Passive immunization with a gp41t-antibody. (a) ELISA assays of sera and CVF at the time points shown. Total IgG and 4.9C titers from two rhesus macaques passively administered either 25 or 50 mg/kg of 4.9C monoclonal antibody. Concentration of 4.9C with 95% confidence intervals in the serum is given in the table below obtained from a 4.9C standard curve (b), western blot analyses and comparisons of antibodies reactive with oligomeric gp41t (gp160 and gp80 bands) in sera and vaginal and cervical tissue extracts following infusion of 25 or 50 mg/kg of a rhesus monoclonal antibody 4.9C, which reacts in western blot with oligomeric gp41t indistinguishably from SIV mac239 Dnef vaccinated animals at 20 weeks. Sample time points correspond to those oligomeric gp41 to sera from SIV mac239 Dnef vaccinated animals [8] ; or a two-fold higher dose of 50 mg/kg. The levels of antigp41t IgG levels in the circulation were comparable in ELISA and western blot assays for the 25 and 50 mg/kg doses (Fig. 5a ), but levels in the CVL were slightly higher at the higher dose, and reactivity with oligomeric gp41t in western blot was only detected in cervical vaginal tissue extracts at 50 mg/kg, even though at about 10-fold lower levels than at 20 weeks after SIV mac239 Dnef vaccination and animals immunized with gp41t-liposomes ( Fig. 5b, right panels) . Importantly, the cervical reserve epithelium was only detectably stained by RIHC for gp41t antibodies at the 50 mg/kg dose (Fig. 5c ).
Discussion
Daniel et al. [3] first showed that i.v. inoculation of SIV mac239 Dnef SIV resulted in attenuated infection that subsequently provided protection against WT viral challenge. The superior protection against WT virus challenge by parenteral and mucosal routes in subsequent studies compared to other approaches was impressive [4] [5] [6] [7] , but the safety issues documented soon thereafter with this approach [9, 10] precluded advancing this concept to development of an effective HIV vaccine.
Nonetheless, protection conferred by live-attenuated SIV vaccines clearly provided a rationale to identify correlates of protection to guide HIV-1 vaccine design. We recently discovered one correlate of the maturation of significant protection manifest at 15-20 weeks postvaccination but not at 5 weeks, in the local production of antibodies to gp41t that are concentrated on the path of virus entry by the neonatal Fc receptor in cervical reserve epithelium and basal vaginal epithelium [8] . Here we show in a pilot experiment that repetitive immunization with liposomal nanoparticles bearing gp41t and adjuvants can generate sufficiently high levels of antibodies to be detectable in FRT by western blot assays of cervical vaginal tissue extracts and RIHC-staining for gp41t-antibodies in FcRnþ cervical epithelium.
Reproducing key features of live-attenuated vaccination correlates of protection with immunogens and adjuvants by a strategy analogous to persistent infection and antigen exposure is encouraging. However, this strategy did not result in recruitment of plasma cells and induction of ectopic follicles that create the system of local antibody production previously documented in SIV mac239 Dnef vaccinated animals [8] . The passive immunization experiment is consistent with the hypothesis that sufficient IgG must be delivered to the FRT to result in detectable antibody in FcRnþ epithelium, presumably reflecting saturation of the receptor for detection by RIHC of antibodies in the cells. Immunization with gp41t-liposomal nanoparticles did generate antibody levels in FRT tissues higher than passive immunization with 50 mg/kg of a gp41t antibody and comparable to SIV mac239 Dnef vaccinated animals at 20 weeks, where about half of the animals have sterilizing immunity against high-dose vaginal challenge. Future studies must now be carried out to determine whether these levels of antigp41 antibodies correlate with protection. If not, we speculate that a next logical step in exploring ways to reproduce the protection afforded by SIV mac239 Dnef vaccination would be a systemic immunization strategy, combined with a 'pull' with local antigen exposure to try to generate a local antibody production system that would provide protection, as has been shown for T-cell protection against vaginal HSV-2 challenge [32] . immunization experiments, evaluated serum and CVF Ig by ELISA and western blot, prepared figures and helped to write the manuscript. M.S.M. incorporated protein into liposomes for immunizations, prepared figures and helped to write the manuscript. K.A.R. and F.V. performed the rhesus macaque experiments. L.D. evaluated serum and CVF levels of antibodies by quantitative western blotting. L.S. performed the neutralization assays. J.E.R. generated the rhesus version of monoclonal antibody 4.9C for the passive immunization experiments. E.A.F. helped with protein production and purification. R.A. helped prepare figures. All the authors analyzed the data and helped write the manuscript. This work was supported by National Institutes of Health Grants R01 AI102625 and P30 AI036214. was produced by the NIH Nonhuman Primate Reagent Resource funded by NIH grant OD010976 and NIAID contract HHSN272200130031C. Portions of this work were facilitated by the Protein Expression and Proteomics Core of the University of California, San Diego, Center for AIDS Research (CFAR).
